Kymera Therapeutics

biopharmaceutical company

KYMR Nasdaq ISIN US5015751044 SEC CIK 1815442
Follow Kymera Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $0 −100% vs same quarter last year
Net income −$132M −60.6% vs same quarter last year
EPS, diluted −$1.32 −40.4% vs same quarter last year
Operating cash flow −$77.9M −187.4% vs same quarter last year
Revenue by quarter
$7.4M
$22.1M
$11.5M
$2.8M
$2.9M
$34.4M
$65M
$0
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income8 fiscal years
$0$20M$40M$60M$80MFY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenue
FY25$39.2M
FY24$47.1M
FY23$78.6M
FY22$46.8M
FY21$72.8M
FY20$34M
FY19$2.9M
FY18-
MarginsShare of revenue
  • Gross margin
  • Operating margin
−1500%−1000%−500%0%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating margin
FY250%−891.1%
FY240%−555.8%
FY230%−210.6%
FY220%−344.4%
FY21-−138%
FY20-−136.1%
FY19-−1438.5%
FY18--
Free cash flowOperating cash flow minus capital expenditure
−$300M−$200M−$100M$0$100MFY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$234.3M
FY24−$207.3M
FY23−$137.3M
FY22−$155.9M
FY21−$130.5M
FY20$79M
FY19$17.4M
FY18-